Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM5IPUS)

Drug Name

SPI-014 Drug Info

Synonyms

SPI-1802; SPI-1810; Amyloid beta peptide 1-42 deposition inhibitor (AD), Satori; Gamma-secretase modulators (Alzheimers disease), Satori Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]
Hypophosphatasia	5C64.3	Phase 1	[1]

Cross-matching ID

PubChem CID: 46221695
CAS Number: CAS 1347739-77-8
TTD Drug ID: DM5IPUS

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gamma-secretase (GS)	TT9W8GU	APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Gamma-secretase (GS)	DTT	APH1A	7.23	7.775	7.538	7.928

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Alzheimer disease

ICD Disease Classification

8A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Gamma-secretase (GS)	DTT	APH1A; APH1B; NCSTN; PSENEN; PSEN1	1.47E-02	-0.09	-0.37

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01560884) Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb. U.S. National Institutes of Health.
2	Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756.